Odanacatib
Sponsors
Merck Sharp & Dohme LLC
Conditions
Breast CancerMetastatic Bone DiseaseOsteoporosisOsteoporosis PostmenopausalPostmenopausal OsteoporosisProstate Cancer
Phase 1
A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)
CompletedNCT00770159
Start: 2004-11-30End: 2005-11-30Updated: 2016-02-05
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
CompletedNCT00769418
Start: 2004-09-30End: 2006-09-30Updated: 2015-08-19
A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)
CompletedNCT00863525
Start: 2004-11-30End: 2006-06-30Updated: 2015-08-19
A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers
CompletedNCT00863590
Start: 2004-06-30End: 2008-08-31Updated: 2015-08-19
Safety and Tolerability of Odanacatib (0822-059)
CompletedNCT01068262
Start: 2009-12-08End: 2010-05-02Updated: 2018-08-28
A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)
TerminatedNCT01630616
Start: 2013-03-12End: 2016-07-14Updated: 2018-08-28
Phase 2
A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
CompletedNCT00112437
Start: 2005-06-24End: 2016-01-20Updated: 2018-01-24
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
CompletedNCT00399802
Start: 2006-11-16End: 2007-12-05Updated: 2018-08-16
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
CompletedNCT00620113
Start: 2007-12-03End: 2009-05-29Updated: 2018-08-27
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
CompletedNCT00885170
Start: 2009-04-13End: 2011-09-15Updated: 2018-08-28
Phase 3
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
TerminatedNCT00529373
Start: 2007-09-13End: 2017-02-01Updated: 2024-06-11
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
WithdrawnNCT00691899
Start: 2008-09-30End: 2008-09-30Updated: 2016-08-12
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
CompletedNCT00729183
Start: 2008-10-02End: 2011-03-21Updated: 2018-08-27
A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)
CompletedNCT01120600
Start: 2010-06-09End: 2013-07-22Updated: 2018-08-28
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
WithdrawnNCT01552122
Start: 2012-05-31End: 2015-02-28Updated: 2015-08-27
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
TerminatedNCT01803607
Start: 2013-03-14End: 2014-11-11Updated: 2019-09-04